Biohaven (BHVN) Non-Current Assets (2021 - 2026)
Biohaven (BHVN) reported Non-Current Assets of $80.8 million for Q1 2026, up 6.0% on a YoY basis from $76.2 million in Q1 2025, and down 2.84% sequentially from $83.1 million in Q4 2025.
Biohaven (BHVN) Non-Current Assets (2021 - 2026) Analysis & Trends
Biohaven (BHVN) has 6 years of Non-Current Assets data on file, last reported at $80.8 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 6.0% year-over-year to $80.8 million; the trailing twelve-month figure through Mar 2026 stood at $325.0 million (up 10.45% YoY), and the FY2025 full-year result was $83.1 million, up 8.46% from the prior year.
- Non-Current Assets retreated to $80.8 million in Q1 2026, from $83.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $85.5 million in Q3 2025 to a low of $55.1 million in Q3 2022.
- A 5-year average of $73.9 million and a median of $74.0 million in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets soared 58.38% in 2022 and slipped 5.75% in 2024, its largest moves.
- Tracing BHVN's Non-Current Assets over 5 years: stood at $74.8 million in 2022, then slipped by 5.41% to $70.8 million in 2023, then climbed by 8.29% to $76.6 million in 2024, then increased by 8.46% to $83.1 million in 2025, then slipped by 2.84% to $80.8 million in 2026.
- Business Quant data shows BHVN's Non-Current Assets at $80.8 million in Q1 2026, $83.1 million in Q4 2025, and $85.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Biohaven | 2.16 Bn | 1.81 Bn | - | 80.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.76 Mn |
| Dec 31, 2025 | 83.12 Mn |
| Sep 30, 2025 | 85.51 Mn |
| Jun 30, 2025 | 75.59 Mn |
| Mar 31, 2025 | 76.19 Mn |
| Dec 31, 2024 | 76.64 Mn |
| Sep 30, 2024 | 70.02 Mn |
| Jun 30, 2024 | 71.37 Mn |
| Mar 31, 2024 | 69.79 Mn |
| Dec 31, 2023 | 70.77 Mn |
| Sep 30, 2023 | 72.17 Mn |
| Jun 30, 2023 | 72.62 Mn |
| Mar 31, 2023 | 74.05 Mn |
| Dec 31, 2022 | 74.82 Mn |
| Sep 30, 2022 | 55.10 Mn |
| Dec 31, 2021 | 47.24 Mn |